Skip to main content

Advertisement

SpringerLink
Log in

Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purposes

The prognosis of localized extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), has improved with the development of chemoradiotherapy. However, conventional extended-field radiotherapy may cause optic disorders. Our group has employed smaller radiation fields in an attempt to avoid toxicity. The efficacy and toxicity of treatments were evaluated.

Materials and methods

Chemoradiotherapy was delivered with a shrinking-field radiotherapy strategy. The endpoints of this study were overall survival (OS), local control (LC), progression-free survival (PFS), and toxicity.

Results

Fifteen patients with localized ENKTL were treated. After irradiation (median, 40 Gy) to the tumor plus a prophylactic volume, a reduced treatment volume to the tumor was boosted (median, 10 Gy). Twelve patients underwent chemoradiotherapy and 3 patients received radiotherapy alone. A complete response was achieved in 12 and a partial response in 3 patients. The 5-year OS, PFS, and LC rates were 80, 67, and 93 %, respectively. Distant recurrence occurred in 4 patients and locoregional and distant recurrence in 1 patient. Cataract (grade 3) and dry eye (grade 2) were observed as late adverse events in 1 patient each.

Conclusions

Sufficiently high OS and LC were achieved with acceptable toxicities. Appropriate target volumes may be smaller with newer chemotherapy regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

    Article  PubMed  Google Scholar 

  2. Kwong YL. The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. J Clin Exp Hematop. 2011;51:21–8.

    Article  PubMed  Google Scholar 

  3. Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int J Hematol. 2012;96:562–71.

    Article  PubMed  Google Scholar 

  4. Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. Spectrum of Epstein-Barr virus-related disease: a pictorial review. Jpn J Radiol. 2009;27:4–19.

    Article  PubMed  Google Scholar 

  5. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, et al. First-line combination of gemcitabine, oxaliplatin, and l-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348–55.

    Article  CAS  PubMed  Google Scholar 

  6. Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, et al. Phase 2 trial of “sandwich” l-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118:3294–301.

    Article  CAS  PubMed  Google Scholar 

  7. Lin N, Song Y, Zheng W, Tu M, Xie Y, Wang X, et al. A prospective phase II study of l-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type. J Hematol Oncol. 2013;6:44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594–600.

    Article  CAS  PubMed  Google Scholar 

  9. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410–6.

    Article  CAS  PubMed  Google Scholar 

  10. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012;30:4044–6.

    Article  PubMed  Google Scholar 

  11. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106:609–15.

    Article  PubMed  Google Scholar 

  12. Oh D, Ahn YC, Kim SJ, Kim WS, Ko YH. Concurrent chemoradiation therapy followed by consolidation chemotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys. 2015;93:677–83.

    Article  PubMed  Google Scholar 

  13. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27:6027–32.

    Article  CAS  PubMed  Google Scholar 

  14. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  15. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.

    Article  PubMed  Google Scholar 

  16. Shibamoto Y, Naruse A, Fukuma H, Ayakawa S, Sugie C, Tomita N. Influence of contrast materials on dose calculation in radiotherapy planning using computed tomography for tumors at various anatomical regions: a prospective study. Radiother Oncol. 2007;84:52–5.

    Article  CAS  PubMed  Google Scholar 

  17. Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59:1127–37.

    Article  PubMed  Google Scholar 

  18. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–53.

    CAS  PubMed  Google Scholar 

  19. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45:1388–95.

    Article  CAS  PubMed  Google Scholar 

  20. Wilson WH. Treatment strategies for aggressive lymphomas: what works? Hematology Am Soc Hematol Educ Program. 2013;2013:584–90.

    Article  PubMed  Google Scholar 

  21. Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.

    Article  PubMed  Google Scholar 

  22. Shibamoto Y, Jeremic B. Biologic premises of combined radiation therapy and chemotherapy in lung cancer. Hematol Oncol Clin North Am. 2004;18:29–40.

    Article  PubMed  Google Scholar 

  23. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25:4096–103.

    Article  CAS  PubMed  Google Scholar 

  24. Murai T, Shibamoto Y, Manabe Y, Murata R, Sugie C, Hayashi A, et al. Intensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical mode. Radiat Oncol. 2013;8:68.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yang Y, Zhu Y, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126:1424–32.

    Article  CAS  PubMed  Google Scholar 

  26. Huang MJ, Jiang Y, Liu WP, Li ZP, Li M, Zhou L, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166–74.

    Article  PubMed  Google Scholar 

  27. Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res (Gann). 1986;77:908–15.

    CAS  PubMed  Google Scholar 

  28. Murata R, Shibamoto Y, Sasai K, Oya N, Shibata T, Takagi T, et al. Reoxygenation after single irradiation in rodent tumors of different types and sizes. Int J Radiat Oncol Biol Phys. 1996;34:859–65.

    Article  CAS  PubMed  Google Scholar 

  29. Wang H, Li YX, Wang WH, Jin J, Dai JR, Wang SL, et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82:1115–21.

    Article  PubMed  Google Scholar 

  30. Shen Q, Ma X, Hu W, Chen L, Huang J, Guo Y. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results. Radiat Oncol. 2013;8:152.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Manabe Y, Shibamoto Y, Sugie C, Hayashi A, Murai T, Yanagi T, et al. Helical and static-port tomotherapy using the newly-developed dynamic jaws technology for lung cancer. Technol Cancer Res Treat. 2014;14:583–91.

    PubMed  Google Scholar 

  32. Kumar G, Rawat S, Puri A, Sharma MK, Chadha P, Babu AG, et al. Analysis of dose-volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT. Jpn J Radiol. 2012;30:18–24.

    Article  PubMed  Google Scholar 

  33. Ken S, Vieillevigne L, Franceries X, Simon L, Supper C, Lotterie JA, et al. Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. Radiat Oncol. 2013;8:1.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank all of the patients who participated in the present study and Dr. Natsuko Takama, Dr. Toru Matsui, Dr. Yoshihiko Manabe and Dr. Takeshi Tamura for helping this study.

Author information

Authors and Affiliations

  1. Nagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1, Hirate-cho, Kita-ku, Nagoya, Aichi, 462-8508, Japan

    Yukiko Hattori & Hiromitsu Iwata

  2. Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan

    Yukiko Hattori, Taro Murai, Hiromitsu Iwata & Yuta Shibamoto

  3. Department of Radiology, Nagoya Daini Red Cross Hospital, 2-9 Myoken-cho, Syowa-ku, Nagoya, Aichi, 466-8650, Japan

    Kaoru Uchiyama

  4. Department of Radiology, Narita Memorial Hospital, 134, Haneihonmachi, Toyohashi, Aichi, 441-8029, Japan

    Mikio Mimura

  5. Department of Radiology, National Hospital Organization Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan

    Eriko Kato

  6. Department of Radiation Oncology, Suzuka General Hospital, 1275-53, Yamanoue, Yasuzuka-cho, Suzuka, Mie, 513-0818, Japan

    Rumi Murata

Authors
  1. Yukiko Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taro Murai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiromitsu Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kaoru Uchiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mikio Mimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eriko Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rumi Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuta Shibamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukiko Hattori.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hattori, Y., Murai, T., Iwata, H. et al. Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience. Jpn J Radiol 34, 292–299 (2016). https://doi.org/10.1007/s11604-016-0524-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-016-0524-8

Keywords

Search

Navigation